NMNAT3, human recombinant protein
Nicotinamide Mononucleotide Adenylyl-transferase 3; NMN Adenylyltransferase 3; NaMN Adenylyltransfer
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q96T66 |
---|---|
Concentration | 1 |
Calculated MW | ~27.0 kDa (monomer). Human full-length NMNAT3 (aa 1-252) is fused at the N-terminus to a His-tag. |
Gene ID | 349565 |
---|---|
Gene Symbol | NMNAT3 |
Other Names | Nicotinamide Mononucleotide Adenylyl-transferase 3; NMN Adenylyltransferase 3; NaMN Adenylyltransferase 3; EC 2.7.7.18; EC 2.7.7.1 |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Results | ≥ 2U/mg protein. One unit is defined as the amount of enzyme that synthesizes 1 µmol of NAD+ per min. |
Target/Specificity | NMNAT3 |
Format | Liquid |
Storage | -20°C; 1 mg/ml in 50 mM sodium phosphate, pH 8.0 containing 300 mM sodium chloride, 1 mM DTT and 10% glycerol. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This is the Mitochondrial NMNAT isoform. It catalyzes the formation of NAD+ from nicotinamide mononucleotide (NMN) and ATP. It can also use the deamidated form of nicotinic acid mononucleotide (NAMN) as substrate with the same efficiency. It can use tiazofurin monophosphate as substrate. It can also use GTP and ITP as nucleotide donors. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD+. For the pyrophosphorolytic activity, mitochondrial NMNAT isoform can use NAD (+), NADH, NAAD, nicotinic acid adenine dinucleotide phosphate (NHD), nicotinamide guanine dinucleotide (NGD) as substrates. It fails to cleave phosphorylated dinucleotides NADP+, NADPH and NAADP+. It protects against axonal degeneration following injury.
References
Wang Y.-G.,et al.Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Muzny D.M.,et al.Nature 440:1194-1198(2006).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Berger F.,et al.J. Biol. Chem. 280:36334-36341(2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.